Predrag Sikirics group (School of Medicine, University of Zagreb, 1991 ) Most common experimental dose in animal studies: 10 g/kg intraperitoneally or per os, daily Standard targeted pathways: VEGFR2 angiogenesis, NO synthase , 5-HT2A serotonin receptor, dopamine D2 receptor Clinical program in Croatia halted at Phase 2 (Crohns disease) WADA Prohibited List: added in 2022 to category S0 (Non-Approved Substances) Reference sources (PubMed) Sikiric P
Copper ions from GHK-Cu primarily block type 1
Most users report 4-8 pounds of fat loss (not just weight loss - actual fat loss while maintaining or even gaining muscle)
A comprehensive pre-treatment panel typically includes a Complete Metabolic Panel (CMP) to assess liver and kidney function, a Complete Blood Count (CBC), thyroid function tests (TSH, Free T3, Free T4), fasting glucose and insulin levels, HbA1c, and a lipid panel